Your browser doesn't support javascript.
loading
Identifying monoclonal gammopathy of undetermined significance from electronic health records.
Tanenbaum, Hilary C; Birmann, Brenda M; Bertrand, Kimberly A; Teras, Lauren R; Krishnan, Amrita Y; Pourhassan, Hoda; Goldsmith, Scott; Cannavale, Kimberly; Wang, Sophia S; Chao, Chun R.
Afiliação
  • Tanenbaum HC; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Birmann BM; Scientific Research & Development, Embark Veterinary, Ithaca, New York, USA.
  • Bertrand KA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Teras LR; Slone Epidemiology Center, Boston University, Boston, Massachusetts, USA.
  • Krishnan AY; Intramural Research Department, American Cancer Society, Atlanta, Georgia, USA.
  • Pourhassan H; City of Hope Medical Center, California, USA.
  • Goldsmith S; City of Hope Medical Center, California, USA.
  • Cannavale K; City of Hope Medical Center, California, USA.
  • Wang SS; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Chao CR; City of Hope Medical Center, California, USA.
Cancer Rep (Hoboken) ; 6(3): e1755, 2023 03.
Article em En | MEDLINE | ID: mdl-36464325
ABSTRACT

BACKGROUND:

Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Use of electronic health records may facilitate large-scale epidemiologic research to elucidate risk factors for the progression of MGUS to MM or other lymphoid malignancies.

AIMS:

We evaluated the accuracy of an electronic health records-based approach for identifying clinically diagnosed MGUS cases for inclusion in studies of patient outcomes/ progression risk. METHODS AND

RESULTS:

Data were retrieved from Kaiser Permanente Southern California's comprehensive electronic health records, which contain documentation of all outpatient and inpatient visits, laboratory tests, diagnosis codes and a cancer registry. We ascertained potential MGUS cases diagnosed between 2008 and 2014 using the presence of an MGUS ICD-9 diagnosis code (273.1). We initially excluded those diagnosed with MM within 6 months after MGUS diagnosis, then subsequently those with any lymphoid malignancy diagnosis from 2007 to 2014. We reviewed medical charts for 100 randomly selected potential cases for evidence of a physician diagnosis of MGUS, which served as our gold standard for case confirmation. To assess sensitivity, we also investigated the presence of the ICD-9 code in the records of 40 randomly selected and chart review-confirmed MGUS cases among patients with a laboratory report of elevated circulating monoclonal (M-) protein (a key test for MGUS diagnosis) and no subsequent lymphoid malignancy (as described above). The positive predictive value (PPV) for the ICD-9 code was 98%. All MGUS cases confirmed by chart review also had confirmatory laboratory test results. Of the confirmed cases first identified via M-protein test results, 88% also had the ICD-9 diagnosis code.

CONCLUSION:

The diagnosis code-based approach has excellent PPV and likely high sensitivity for detecting clinically diagnosed MGUS. The generalizability of this approach outside an integrated healthcare system warrants further evaluation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Gamopatia Monoclonal de Significância Indeterminada / Mieloma Múltiplo Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Gamopatia Monoclonal de Significância Indeterminada / Mieloma Múltiplo Idioma: En Ano de publicação: 2023 Tipo de documento: Article